PLANEGG-MARTINSRIED, Germany, June 28 /PRNewswire/ --     German drug discovery and development company 4SC AG (DAX: VSC)
(Frankfurt, Prime Standard), based in Martinsried near Munich, reports today
on the successful completion of patient recruitment for the phase IIa
clinical trial with its drug candidate SC12267 for the treatment of patients
suffering from rheumatoid arthritis.

In the three-tiered and placebo-controlled study, patients are
given two doses of SC12267 per day over a three month period and tested for
tolerance and clinical efficacy. The study is being carried out in 13 centres
across Germany, Poland and Serbia. According to plan the study results are
expected for the fourth quarter of 2007.

About Rheumatoid Arthritis:

Rheumatoid Arthritis is a chronic inflammatory joint disease
that afflicts 0.5 - 1% of the population; women are three times more likely
to get arthritis than men are. In the late stage of the disease, irreversible
damage to joint cartilage and bones occurs. Causes of this disease are
genetic as well as autoimmune factors. Besides pain-relieving medicines,
so-called disease-modifying medicines (DMARDs = disease modifying
anti-rheumatic drugs) can be used in treatment. These drugs are used to
induce a healing process.

They differ from other groups of drugs used in the treatment
of rheumatoid diseases, since only they are able to stop or reduce damage
caused from chronic inflammation to the joint cartilage or bone. In the most
favourable cases, some DMARDs can also induce repair of damage to joints and
provide support for the repair of changes that have already occurred.

About SC12267:

SC12267 is a new type of small molecular active agent from the
class of DMARDs used for treatment of autoimmune diseases such as rheumatoid
arthritis or multiple sclerosis. The substance works as a highly selective
inhibitor in the biosynthesis of pyrimidine, which inhibits the proliferation
of fast proliferating cells, in particular the important lymphocytes used for
immune response. The drug candidate originates in 4SC AG's own research
pipeline. In prior pre-clinical and clinical studies, an outstanding potency
and favourable pharmacokinetic characteristics could already be observed in
animal testing, and a tolerable dosage without relevant side effects on test
subjects was determined.

About 4SC AG:

4SC AG (ISIN: DE0005753818) has been listed in the Prime Standard of
Frankfurt Stock Exchange since 15 December 2005. Founded in 1997 and now with
a staff of 60, the company develops novel drug candidates for inflammatory
diseases and cancer using a cheminformatics based technology platform.
Traditional high throughput screening of therapeutic agents has been
transferred from the lab to the computer. Thus, the company offers
substantial cost and time advantages as well as increased success rates in
drug development. 4SC AG uses its patented technology platform to create a
sustainable product pipeline for active agents that are developed in early
clinical phases ("proof of concept") and subsequently result in upfront and
milestone payments as well as participation in sales generated by
out-licensed products to the pharmaceutical industry. There are currently six
projects in the pipeline. The first project on the treatment of rheumatoid
arthritis is currently undergoing clinical phase IIa. Four other product
candidates are in preclinical development and another project is in the
research stage. Furthermore, the company has its technology platform in
co-operation projects with biotech and pharma companies and is already
generating initial revenues.

Legal Note

This document may contain projections or estimates relating to plans and
objectives relating to our future operations, products, or services; future
financial results; or assumptions underlying or relating to any such
statements; each of which constitutes a forward-looking statement subject to
risks and uncertainties, many of which are beyond our control. Actual results
could differ materially, depending on a number of factors.

For more information please contact:

    Bettina von Klitzing
    Manager Investor Relations und Public Relations
    4SC AG
    Tel.: +49-(0)-89-70-07-63-0
    Bettina.von.klitzing@4sc.com